Search Result

Results for "

Tuberculosis+(TB)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (5) Antifolate (1) Autophagy (1) Bacterial (25) DNA/RNA Synthesis (2) Environmental Pollutants (1) Isotope-Labeled Compounds (1) mTOR (1) Phosphodiesterase (PDE) (1) Reference Standards (3) TNF Receptor (2)
By Research Areas:	Cancer (2) Infection (24) Inflammation/Immunology (12) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1906

Streptomycin 45+ Cited Publications Agrept; Agrimycin; Streptomycin A	Environmental Pollutants Antibiotic Bacterial	Infection Neurological Disease
Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .

HY-105099

Rifalazil KRM-1648; ABI-1648	Antibiotic DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .

HY-112324

Terizidone	Bacterial	Infection
Terizidone is an antibacterial agent, and shows bacteriostatic activity. Terizidone can be used in tuberculosis (TB) research .

HY-111086

DG70 GSK1733953A	Bacterial	Infection
DG70 (GSK1733953A), a biphenyl amide, is a respiration inhibitor in Mycobacterium tuberculosis, inhibits MenG activity with an IC₅₀ value of 2.6 ± 0.6 μM. DG70 inhibits the catalytic methylation of Mycobacterium tuberculosis demethylmenaquinone methyltransferase enzymes. DG70 can be used for Tuberculosis (TB) research .

HY-B1906R

Streptomycin (Standard) Agrept (Standard); Agrimycin (Standard); Streptomycin A (Standard)	Reference Standards Antibiotic Bacterial	Infection Neurological Disease
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-112091

GSK2200150A	Bacterial	Infection
GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.

HY-142031

4-Piperidinecarboxamide	Bacterial	Infection
4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .

HY-151514

Antituberculosis agent-5	Bacterial	Infection
Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC₅₀ value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .

HY-172349

JNJ-2901	Bacterial	Infection
JNJ-2901 is an inhibitor of *M. tuberculosis* cytochrome bc1:aa3*. JNJ-2901 reduces bacterial load in the acute/chronic mouse infection models of M. tuberculosis* H37Rv-ΔcydAB. JNJ-2901 can be used in tuberculosis (TB) research .

HY-144727

Anti-inflammatory agent 11	Bacterial TNF Receptor	Infection Inflammation/Immunology
Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC₅₀ (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research .

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .

HY-151354

Antibacterial agent 121	Bacterial	Infection
Antibacterial agent 121 (Compound 10) is an antibacterial agent. Antibacterial agent 121 shows anti-mycobacterial and anti-inflammatory activities and can be used in Tuberculosis (TB) research .

HY-155460

Pks13-TE inhibitor 4	Bacterial	Infection
Pks13-TE inhibitor 4 (compound 44) is an oxadiazole series Pks13 inhibitor that effectively inhibits tuberculosis (TB) and resolves its drug resistance .

HY-147661

DHFR-IN-2	Antifolate	Infection
DHFR-IN-2 (compound 4e) is a potent and uncompetitive inhibitor for MtDHFR (dihydrofolate reductase from M. tuberculosis), with an IC₅₀ of 7 μM. DHFR-IN-2 can be used for tuberculosis (TB) research .

HY-173617

GDI-5755 SAM002706100	Bacterial	Infection Inflammation/Immunology
GDI-5755 (SAM002706100), an antibacterial agent by inhibiting ClpP1P2, inhibits the growth of Mtb and M. bovis BCG, the model organism of mycobacteria. GDI-5755 can be used in the research for tuberculosis (TB) .

HY-167242

ZTB23(R)	Bacterial	Infection
ZTB23(R) is a potent and selective Mycobacterium tuberculosis zinc metalloproteinase-1 (Zmp1) inhibitor with K_i value of 0.054 μM. ZTB23(R) can be used for tuberculosis (TB) research .

HY-W702303

Terizidone-15N2,d6	Isotope-Labeled Compounds Bacterial	Infection
Terizidone- ¹⁵N₂,d₆ is the deuterium and ¹⁵N-labeled Terizidone (HY-112324). Terizidone is an antibacterial agent, and shows bacteriostatic activity. Terizidone can be used in tuberculosis (TB) research .

HY-151806

HadAB-IN-1	Bacterial	Infection Inflammation/Immunology
HadAB-IN-1 is a potent HadAB inhibitor. HadAB-IN-1 inhibits HadAB enzyme complexes activity with an IC₅₀ value of 0.03 μM. HadAB-IN-1 also affects mycolic acid biosynthesis in Mycobacterium tuberculosis* (Mtb). HadAB-IN-1 can be used for the research of tuberculosis (TB*) .

HY-152035

Mycobacterial Zmp1-IN-1	Bacterial	Infection Inflammation/Immunology
Mycobacterial Zmp1-IN-1 is a mycobacterial zinc metalloprotease-1 (Zmp1) inhibitor. Mycobacterial Zmp1-IN-1 has anti-mycobacterial activity for Mtb H37Ra in dose-dependent inhibition. Mycobacterial Zmp1-IN-1 can be used for the research of tuberculosis (TB) .

HY-144737

Anti-inflammatory agent 15	Bacterial TNF Receptor	Infection Inflammation/Immunology
Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC₅₀ (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research .

HY-107813R

Amikacin sulfate (Standard) BAY 41-6551 sulfate (Standard)	Reference Standards Bacterial Antibiotic	Infection Cancer
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-170970

Mtb-IN-10	Bacterial	Infection
Mtb-IN-10 (Compound P15) is a Rv1625c/Cya activator that regulates cAMP metabolism to influence the growth of Mycobacterium tuberculosis (Mtb). Mtb-IN-10 exhibits an EC₅₀ of 1.96 µM in an Mtb-infected macrophage model and demonstrates 58.0% oral bioavailability in mice at a 20 mg/kg dose. It may regulate intracellular signaling and disrupt cholesterol metabolism in Mtb, thereby inhibiting bacterial proliferation. Mtb-IN-10 holds potential for tuberculosis (TB) research, particularly for combating multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains .

HY-105099R

Rifalazil (Standard) KRM-1648 (Standard); ABI-1648 (Standard)	Antibiotic Reference Standards DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].

HY-179532

Antimycobacterial agent-14	Bacterial	Inflammation/Immunology
Antimycobacterial agent-14 (compound 20s) is an antimycobacterial agent with potent activity against Mycobacterium tuberculosis (M.tb) H37Ra strain with a MIC of 11.37 μM. Antimycobacterial agent-14 can be used for tuberculosis (TB) research .

HY-W791994A

BVL3572S	Bacterial	Inflammation/Immunology
BVL3572S, a hydroxamic acid derivative, exhibits potent bactericidal activity against Mycobacterium tuberculosis (Mtb) with a MIC₉₀ of 1.7 µM. BVL3572S inhibits pyridoxal phosphate (PLP)-dependent aminotransferases HisC and AlaA to kill Mtb. BVL3572S can be used for tuberculosis (TB) research .

HY-179444

Antituberculosis agent-17	Bacterial	Inflammation/Immunology
Antituberculosis agent-17 (compound 21) is a potent and selective antituberculosis agent. Antituberculosis agent-17 displays excellent anti-Tuberculosis* (TB) activity against H37Rv, MDR and XDR strains of TB (MIC* = 0.2-0.78 μM). Antituberculosis agent-17 exhibits selectivity for Mycobacterium tuberculosis over selected non-TB forming mycobacteria and bacteria. Antituberculosis agent-17 can be used for TB research .

HY-181008

Antitubercular agent-56	Bacterial	Infection Inflammation/Immunology
Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (K_d = 9.39 μM; IC₅₀ = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB) .

Cat. No.	Product Name

HY-L142

*Anti-tuberculosis* Compound Library**	151 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 151 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

151 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 151 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Category	Target	Chemical Structure